NeuroOne Medical TechnologiesNMTC
NMTC
About: NeuroOne Medical Technologies Corp operates as a medical technology company. It is focused on the development and commercialization of thin-film electrode technology for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording, brain stimulation, and ablation solutions for patients suffering from brain-related disorders. The company business is in one operating segment, which is the business of development and commercialization of products related to comprehensive neuromodulation cEEG and sEEG recording, monitoring, ablation, and brain stimulation solutions.
Employees: 17
0
Funds holding %
of 6,815 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
17% more funds holding
Funds holding: 18 [Q2] → 21 (+3) [Q3]
5.38% less ownership
Funds ownership: 13.24% [Q2] → 7.87% (-5.38%) [Q3]
19% less capital invested
Capital invested by funds: $2.95M [Q2] → $2.39M (-$559K) [Q3]
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
100% less funds holding in top 10
Funds holding in top 10: 1 [Q2] → 0 (-1) [Q3]
Research analyst outlook
We haven’t received any recent analyst ratings for NMTC.
Financial journalist opinion
Based on 5 articles about NMTC published over the past 30 days
Neutral
GlobeNewsWire
4 days ago
NeuroOne® Announces Preliminary Unaudited First Quarter Fiscal 2025 Revenue Increase to a Record $6.2 Million
First Quarter Fiscal 2025 Revenue Includes a One-Time Upfront Payment of $3.0 Million in Collaboration Revenue from Zimmer Biomet and $3.2M in Product Revenue
Neutral
Seeking Alpha
1 week ago
Stock Picks From Seeking Alpha's December 2024 New Analysts
In December, we welcomed 29 new analysts to Seeking Alpha and in this article we are showcasing their stock picks and investment strategies. Five buy picks are highlighted on Viasat, Newmont, NeuroOne Medical, X-Fab Silicon Foundries, and ArcerlorMittal. Analysts' recommendations range from Strong Buy to Strong Sell, covering diverse sectors such as healthcare, technology, energy, and consumer goods.
Neutral
GlobeNewsWire
1 week ago
NeuroOne® Announces Virtual Investor Webinar on January 9, 2025 at 11:00 a.m. EST
Company to Provide Overview of Business Model and Expected Revenue Acceleration in Fiscal Year 2025 EDEN PRAIRIE, Minn., Jan. 03, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today that it will hold a virtual roadshow webinar to discuss its business operations and recent updates.
Neutral
Seeking Alpha
4 weeks ago
NeuroOne Medical Technologies Corporation (NMTC) Q4 2024 Earnings Call Transcript
NeuroOne Medical Technologies Corporation (NASDAQ:NMTC ) Q4 2024 Earnings Conference Call December 17, 2024 9:00 AM ET Company Participants Dave Rosa - Chief Executive Officer Ron McClurg - Chief Financial Officer Conference Call Participants Operator Good day, ladies and gentlemen. Welcome to the NeuroOne Fourth Quarter and Fiscal Year-End 2024 Earnings Call.
Neutral
GlobeNewsWire
4 weeks ago
NeuroOne® Product Revenue Increases 77% to $3.5 Million in Fiscal 2024: Expects Product Revenue to Increase at Least 132% to at Least $8 Million in Fiscal 2025
Company's Exclusive Distribution Agreement with Zimmer Biomet included $3.0 Million Upfront Payment: Expected to Drive Revenue and Expand Margins Significantly
Positive
Seeking Alpha
1 month ago
NeuroOne Medical Technologies: A Small-Cap Electrode Technology Play With Multiple Catalysts Ahead
NeuroOne is a commercial stage medical device company with FDA-cleared electrodes used in prominent U.S. medical centers for epilepsy diagnosis and treatment. NMTC is partnered with Zimmer Biomet, a $21 billion medical device company, and is close to reaching cash flow break even, reducing shareholder dilution. NMTC's electrodes are superior due to their ability to provide real-time, high-resolution brain signal recordings and stimulate brain tissue, aiding in precise neurosurgical procedures.
Neutral
Accesswire
2 months ago
NeuroOne Medical Technologies Corporation to Present at November 21st Virtual Investor Summit Microcap Event
EDEN PRAIRIE, MN / ACCESSWIRE / November 13, 2024 / NeuroOne Medical Technologies Corporation (Nasdaq:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it will be participating in the Virtual Investor Summit Microcap Event. The company will be available for 1-on-1 meetings throughout the day in addition to their presentation.
Neutral
GlobeNewsWire
2 months ago
NeuroOne® Announces Expansion of Existing Distribution Agreement with Zimmer Biomet for Commercialization of OneRF™ Ablation System
License Provides Exclusive Commercialization Rights for US Distribution and Certain OUS MarketsAgreement expected to boost NeuroOne sales revenue and profitability
Neutral
MCAP MediaWire
2 months ago
NeuroOne® Medical Technologies to Present at the 2024 ThinkEquity Conference
EDEN PRAIRIE, Minn.
Neutral
GlobeNewsWire
2 months ago
NeuroOne® Medical Technologies to Present at the 2024 ThinkEquity Conference
EDEN PRAIRIE, Minn., Oct. 24, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it will be participating in The ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York.
Charts implemented using Lightweight Charts™